---
title: "Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 2H | Second half of the year |
| 5-ASA, 5-ASAs, 5ASA | 5-Aminosalicylic acid |
| ABX464, ABX-464 | Abivax development code for obefazimod |
| ABX464-N-Glu, ABX464-NGlc | ABX464 N-glucuronide, a pharmacologically active metabolite of obefazimod |
| ACG | American College of Gastroenterology |
| ACT | Active Ulcerative Colitis Trial (ACT 1 and ACT 2, infliximab) |
| AdjM | Adjusted mean |
| AE, AEs | Adverse event |
| AESI, AESIs | Adverse event of special interest |
| AGA | American Gastroenterological Association |
| AHFS | American Hospital Formulary Service |
| AhR | Aryl hydrocarbon receptor |
| aHR | Adjusted hazard ratio |
| ALT | Alanine aminotransferase |
| ANCOVA | Analysis of covariance |
| ANOVA | Analysis of variance |
| ASCA | Anti-Saccharomyces cerevisiae antibodies |
| ASP | Average sales price |
| AST | Aspartate aminotransferase |
| ASUC | Acute severe ulcerative colitis |
| AT, ATs | Advanced therapy |
| AT-IR, ATIR | Inadequate response to advanced therapy |
| ATC | Anatomical Therapeutic Chemical (classification code) |
| AUC | Area under the concentration-time curve |
| AUC0-inf, AUC0–∞ | Area under the concentration-time curve from time 0 to infinity |
| AUC0-t, AUC0–t | Area under the concentration-time curve from time 0 to the last measurable concentration |
| BDD | Baseline disease duration |
| BGD | Between-group difference |
| BID | Twice daily |
| BMI, BMIs | Body mass index |
| BOLS | Baseline of Open Label Study |
| BSG | British Society of Gastroenterology |
| BTL | Bottle (package description) |
| BU | Bowel urgency |
| CAP | Capsule (package description) |
| CAS | Chemical Abstracts Service |
| CBC | Complete blood count |
| CCL2 | C-C motif chemokine ligand 2 |
| CD | Crohn's disease |
| CD4 | Cluster of differentiation 4 |
| CEST | Central European Summer Time |
| CI | Confidence interval |
| Cmax | Maximum plasma concentration |
| CMH | Cochran-Mantel-Haenszel |
| CMOs | Contract manufacturing organizations |
| CMS | Centers for Medicare & Medicaid Services |
| CMV | Cytomegalovirus |
| COVID-19 | Coronavirus disease 2019 |
| CPK | Creatine phosphokinase |
| CR-I | Coalescing range for incidence |
| CR-P | Coalescing range for prevalence |
| CRC, CRCs | Colorectal cancer |
| CRP | C-reactive protein |
| CRS | Clinical Research Services (CRS Clinical Research Services Management GmbH) |
| CRs | Coalescing ranges |
| CS | Corticosteroid |
| CT | Count (package description) |
| CTC-AE, CTCAE | Common Terminology Criteria for Adverse Events |
| CV, CVs | Cardiovascular; coefficient of variation |
| CXCL12 | C-X-C motif chemokine ligand 12 |
| CY | Calendar year |
| CYP, P450 | Cytochrome P450 |
| CYP1A2 | Cytochrome P450 1A2 |
| D28, D56 | Day 28, day 56 |
| DDI | Drug-drug interaction |
| ddPCR | Droplet digital polymerase chain reaction |
| DILI | Drug-induced liver injury |
| DILIsym | Drug-induced liver injury simulation software |
| DLT | Dose-limiting toxicity |
| DSMB | Data Safety Monitoring Board |
| DSS | Dextran sulfate sodium |
| DVT | Deep vein thrombosis |
| E1, E2, E3 | Montreal classification of disease extent: proctitis (E1), left-sided colitis (E2), extensive colitis (E3) |
| ECCO | European Crohn's and Colitis Organisation |
| ECG | Electrocardiogram |
| ED | Emergency department |
| EEA | European Economic Area |
| EIMs | Extraintestinal manifestations |
| EL3, EL4 | Evidence level 3, evidence level 4 |
| EMA | European Medicines Agency |
| EOS | End of Study |
| EQ-5D | EuroQol 5-Dimension |
| EQ-5D-5L | EuroQol 5-Dimension, 5-Level |
| ER | Emergency room |
| ESR | Erythrocyte sedimentation rate |
| EU | European Union |
| EU5 | France, Germany, Italy, Spain, and the United Kingdom |
| EudraCT | European Union Drug Regulating Authorities Clinical Trials Database |
| evLY | Equal value life-year |
| FACIT-Fatigue | Functional Assessment of Chronic Illness Therapy-Fatigue |
| FAS | Full Analysis Set |
| FC, FCP | Fecal calprotectin |
| FDA | U.S. Food and Drug Administration |
| GM, GMs | Geometric mean |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| GmbH | Gesellschaft mit beschränkter Haftung (limited liability company) |
| HBV | Hepatitis B virus |
| HCP, HCPs | Health care provider |
| HCRU | Health care resource utilization |
| HCUP | Healthcare Cost and Utilization Project |
| HEMI, HEMI1 | Histologic-endoscopic mucosal improvement |
| HIV | Human immunodeficiency virus |
| HLA | Human leukocyte antigen |
| HLA-B27 | Human leukocyte antigen B27 |
| HPA | Hypothalamus-pituitary-adrenal |
| HR | Hazard ratio; hour (in a product description) |
| HRA | Health Research Authority (United Kingdom) |
| HRQoL | Health-related quality of life |
| HSTCL | Hepatosplenic T-cell lymphoma |
| I2 | I-squared statistic of heterogeneity |
| IBD, IBDs | Inflammatory bowel disease |
| IBD-FC | IBD-fibrotic cytokine cocktail |
| IBDQ | Inflammatory Bowel Disease Questionnaire |
| IBSEN | Inflammatory Bowel South-Eastern Norway (cohort study) |
| IC | Indeterminate colitis |
| ICD-10 | International Classification of Diseases, Tenth Revision |
| ICER | Institute for Clinical and Economic Review |
| ICVSC | Independent Cardiovascular Safety Committee |
| ID | Identifier |
| IE, IEs | Intercurrent event |
| IEC-IRB | Independent Ethics Committee-Institutional Review Board |
| IFNγ | Interferon gamma |
| IgG1 | Immunoglobulin G1 |
| IgG1λ | Immunoglobulin G1 lambda |
| IgG4 | Immunoglobulin G4 |
| IL | Interleukin |
| IL-12/23 | Interleukin 12 and interleukin 23 |
| IL-13 | Interleukin 13 |
| IL-17 | Interleukin 17 |
| IL-17A, IL17a | Interleukin 17A |
| IL-22 | Interleukin 22 |
| IL-23, IL23 | Interleukin 23 |
| IL-4, IL4 | Interleukin 4 |
| IL-5 | Interleukin 5 |
| IL-6, IL6 | Interleukin 6 |
| IL10 | Interleukin 10 |
| IL1b | Interleukin 1 beta |
| IL23p19 | p19 subunit of interleukin 23 |
| IL34 | Interleukin 34 |
| IL6r | Interleukin 6 receptor |
| IMP | Investigational medicinal product |
| INN | International Nonproprietary Name |
| IPAA | Ileal pouch-anal anastomosis |
| IQR | Interquartile range |
| IR, IRs | Inadequate response; incidence rate (IR/100 PY) |
| IRA | Ileorectal anastomosis |
| ISB | Induction Study Baseline |
| ITT | Intention-to-treat |
| IUS | Intestinal ultrasound |
| IV | Intravenous |
| IVCS | Intravenous corticosteroids |
| JAK, JAKs | Janus kinase |
| JAK-1 | Janus kinase 1 |
| JAK-IR | Inadequate response to a Janus kinase inhibitor |
| JAKi | Janus kinase inhibitor |
| LANCL2 | Lanthionine synthetase C-like protein 2 |
| LFTs | Liver function tests |
| LIF | Leukemia inhibitory factor |
| LOCF | Last observation carried forward |
| LPS | Lipopolysaccharide |
| LSM, LSMeans | Least squares mean |
| LTE | Long-term extension |
| M1, M2, M3, M12, M24, M48 | Month 1, month 2, month 3, month 12, month 24, month 48 |
| MACE | Major adverse cardiovascular events |
| MCP1 | Monocyte chemoattractant protein 1 |
| MCS | Mayo Clinic Score |
| MES | Mayo endoscopic subscore |
| MIPS | Merit-based Incentive Payment System |
| miR-124, MiR-124, miR124, miRNA-124 | MicroRNA-124 |
| miRNA | MicroRNA |
| MMS, mMS | Modified Mayo Score |
| MMX | Multi-Matrix System |
| MOAs | Mechanisms of action |
| mRNA | Messenger ribonucleic acid |
| MWPC | Meaningful within patient change |
| N/A | Not applicable |
| NBM | Nocturnal bowel movements |
| NC | Not calculated |
| NCI | National Cancer Institute |
| NDA | New Drug Application |
| NHB | Net health benefit |
| NIMP | Non-investigational medicinal product |
| NIS | National Inpatient Sample |
| NMA | Network meta-analysis |
| NMSC, NMSCs | Nonmelanoma skin cancer |
| NNT | Number needed to treat |
| NRI | Nonresponder imputation |
| NRS | Numerical Rating Scale |
| NSAID | Nonsteroidal anti-inflammatory drug |
| NT-proBNP | N-terminal pro-B-type natriuretic peptide |
| NYHA | New York Heart Association |
| OATP1B1, 1B3 | Organic anion-transporting polypeptide 1B1 and 1B3 |
| Obe-25, Obe-50 | Obefazimod 25 mg, obefazimod 50 mg |
| OC | Observed Cases |
| OLE | Open-label extension |
| OLM | Open-label maintenance |
| OR, ORs | Odds ratio |
| pANCA | Perinuclear antineutrophil cytoplasmic antibodies |
| PBMCs | Peripheral blood mononuclear cells |
| PBO | Placebo |
| PBTL | Plastic bottle (package description) |
| PDE-4 | Phosphodiesterase 4 |
| PDs | Protocol deviations |
| Ph.D. | Doctor of Philosophy |
| PI | Principal investigator |
| PIP | Paediatric investigation plan |
| PK | Pharmacokinetics |
| PML | Progressive multifocal leukoencephalopathy |
| pMMS | Partial Modified Mayo Score |
| pMS | Partial Mayo score |
| PP | Per protocol |
| PPAS | Per Protocol Analysis Set |
| pre-mRNA | Precursor messenger ribonucleic acid |
| PRES | Posterior Reversible Encephalopathy Syndrome |
| PRO, PROs | Patient-reported outcome |
| PRO-C3 | N-terminal propeptide of type III collagen |
| PRO2 | Two-item patient-reported outcome (stool frequency and rectal bleeding) |
| PSC | Primary sclerosing cholangitis |
| PY | Patient-years |
| Q3, Q4 | Third quarter, fourth quarter |
| QALY, QALYs | Quality-adjusted life-year |
| QD | Once daily |
| QoL | Quality of life |
| qPCR | Quantitative polymerase chain reaction |
| QT | QT interval of the electrocardiogram |
| QTc | QT interval corrected for heart rate |
| RA | Rheumatoid arthritis |
| RBS | Rectal bleeding subscore |
| RCT, RCTs | Randomized controlled trial |
| RNA | Ribonucleic acid |
| RNAi | RNA interference |
| RR | Risk ratio |
| S1P, S1Ps | Sphingosine-1-phosphate |
| SAE, SAEs | Serious adverse event |
| SAF | Safety Analysis Set |
| SARS Cov-2 | Severe acute respiratory syndrome coronavirus 2 |
| SC | Subcutaneous |
| SCCAI | Simple Clinical Colitis Activity Index |
| SCFA | Short-chain fatty acid |
| SD | Standard deviation |
| SF-36 | 36-Item Short Form Health Survey |
| SFS | Stool frequency subscore |
| SGOT | Serum glutamic-oxaloacetic transaminase |
| SGPT | Serum glutamic-pyruvic transaminase |
| SIBDQ | Short Inflammatory Bowel Disease Questionnaire |
| SIR | Standardized incidence ratio |
| SMR | Standardized mortality ratio |
| STAT3 | Signal transducer and activator of transcription 3 |
| STRIDE-I, STRIDE-II | Selecting Therapeutic Targets in Inflammatory Bowel Disease, first and second consensus |
| t1/2 | Elimination half-life |
| TB | Tuberculosis |
| TEAE, TEAEs | Treatment-emergent adverse event |
| TESAEs | Treatment-emergent serious adverse events |
| TFC | Film-coated tablet (package description) |
| Th1, Th17 | T helper type 1 cell, T helper type 17 cell |
| TIMs | Targeted immune modulators |
| TL1A | Tumor necrosis factor-like ligand 1A |
| Tmax | Time to maximum plasma concentration |
| TMS, tMS | Total Mayo Score |
| TNBS | 2,4,6-Trinitrobenzene sulfonic acid |
| TNF | Tumor necrosis factor |
| TNF-α, TNFα, TNF-alpha | Tumor necrosis factor alpha |
| TPO | Thrombopoietin |
| UC | Ulcerative colitis |
| UEG | United European Gastroenterology |
| UGTIA9 | Uridine diphosphate glucuronosyltransferase 1A9 (printed as UGTIA9 in the source) |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| US, U.S. | United States |
| USA, U.S.A. | United States of America |
| USD | United States dollar |
| V5.0 | Version 5.0 |
| VAS | Visual analog scale |
| VTE | Venous thromboembolism |
| W8, W48, W96, W144 | Week 8, week 48, week 96, week 144 |
| WAC, WACs | Wholesale acquisition cost |
| WHO | World Health Organization |
| WOCBP | Women of childbearing potential |
| WPAI | Work Productivity and Activity Impairment |
| WPAI-UC | Work Productivity and Activity Impairment questionnaire for ulcerative colitis |
| XR | Extended release |
| α-SMA | Alpha-smooth muscle actin |

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
